Development of novel pcr assays to detect azole resistance-mediating mutations of the Aspergillus fumigatus cyp51A gene in primary clinical samples from neutropenic patients

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3905-3910

  Spiess, Birgit ^a   Seifarth, Wolfgang ^a   Merker, Natalia ^a   Howard, Susan J ^b   Reinwald, Mark ^a   Dietz, Anne ^a   Hofmann, Wolf Karsten ^a   Buchheidt, Dieter ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FUNGAL PROTEIN; GENOMIC DNA; ITRACONAZOLE; POSACONAZOLE; PROTEIN CYP51A; PYRROLE; UNCLASSIFIED DRUG; VORICONAZOLE;

AMPLICON; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLUS FUMIGATUS; BRAIN ABSCESS; BROTH DILUTION; CLINICAL LABORATORY; CONTROLLED STUDY; CROSS REACTION; DNA SEQUENCE; FUNGAL STRAIN; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG BIOPSY; LUNG LAVAGE; NEEDLE BIOPSY; NEUTROPENIA; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; TANDEM REPEAT;

ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; AZOLES; DNA, FUNGAL; DRUG RESISTANCE, FUNGAL; HUMANS; MUTATION; NEUTROPENIA; POLYMERASE CHAIN REACTION;

EID: 84862519660     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05902-11     Document Type: Article

References (31)

1. Buchheidt D, et al. 2002. Clinical evaluation of a polymerase chain reaction assay to detect Aspergillus species in bronchoalveolar lavage samples of neutropenic patients. Br. J. Haematol. 116:803-811. (Pubitemid 34226999)
2. Buchheidt D, et al. 2001. Detection of Aspergillus species in blood and bronchoalveolar lavage samples from immunocompromised patients by means of 2-step polymerase chain reaction: clinical results. Clin. Infect. Dis. 33:428-435. (Pubitemid 32709572)
3. Buchheidt D, Hummel M, Schleiermacher D, Spiess B, Hehlmann R. 2004. Current molecular diagnostic approaches to systemic infections with aspergillus species in patients with hematological malignancies. Leuk. Lymphoma 45:463-468. (Pubitemid 38196028)
4. Bueid A, et al. 2010. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J. Antimicrob. Chemother. 65:2116-2118.
5. Chowdhary A, et al. 2012. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J. Antimicrob. Chemother. 67:362-366.
6. Denning DW, et al. 2011. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin. Infect. Dis. 52:1123-1129.
7. Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, Rodriguez-Tudela JL. 2003. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 47:1120-1124.
8. Garcia-Effron G, et al. 2008. Rapid detection of triazole antifungal resistance in Aspergillus fumigatus. J. Clin. Microbiol. 46:1200-1206. (Pubitemid 351563556)
9. Howard SJ, Arendrup MC. 2011. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med. Mycol. 49:90-95.
10. Howard SJ, et al. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15:1068-1076.
11. Howard SJ, et al. 2006. Multi-azole resistance in Aspergillus fumigatus. Int. J. Antimicrob. Agents 28:450-453. (Pubitemid 44740492)
12. Hummel M, et al. 2010. Aspergillus PCR testing: results from a prospective PCR study within the AmBiLoad trial. Eur. J. Haematol. 85:164-169.
13. Hummel M, et al. 2006. Detection of Aspergillus DNA in cerebrospinal fluid from patients with cerebral aspergillosis by a nested PCR assay. J. Clin. Microbiol. 44:3989-3993. (Pubitemid 44737240)
14. Klaassen CH, de Valk HA, Curfs-Breuker IM, Meis JF. 2010. Novel mixed-format real-time PCR assay to detect mutations conferring resistance to triazoles in Aspergillus fumigatus and prevalence of multi-triazole resistance among clinical isolates in the Netherlands. J. Antimicrob. Chemother. 65:901-905.
15. Lockhart SR, et al. 2011. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS Global Surveillance Study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob. Agents Chemother. 55:4465-4468.
16. Maschmeyer G, et al. 2009. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: guidelines of the Infectious Diseases Working Party of the German Society of Haematology and Oncology. Eur. J. Cancer 45:2462-2472.
17. Mellado E, et al. 2007. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob. Agents Chemother. 51:1897-1904. (Pubitemid 46903071)
18. Perlin DS. 2009. Antifungal drug resistance: do molecular methods provide a way forward? Curr. Opin. Infect. Dis. 22:568-573.
19. Rodriguez-Tudela JL, et al. 2008. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 52:2468-2472. (Pubitemid 351915677)
20. Ruhnke M, et al. 2012. Diagnosis of invasive fungal infections in hematology and oncology - guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). Ann. Oncol. 23:823-833.
21. Sambrook J, Fritsch E, Maniatis T. 1989. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
22. Skladny H, et al. 1999. Specific detection of Aspergillus species in blood and bronchoalveolar lavage samples of immunocompromised patients by two-step PCR. J. Clin. Microbiol. 37:3865-3871.
23. Snelders E, et al. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5:219.
24. Spiess B, et al. 2003. Development of a LightCycler PCR assay for detection and quantification of Aspergillus fumigatus DNA in clinical samples from neutropenic patients. J. Clin. Microbiol. 41:1811-1818. (Pubitemid 36576496)
25. Spiess B, et al. 2007. DNA microarray-based detection and identification of fungal pathogens in clinical samples from neutropenic patients. J. Clin. Microbiol. 45:3743-3753. (Pubitemid 350156875)
26. van der Linden JW, et al. 2009. Azole-resistant central nervous system aspergillosis. Clin. Infect. Dis. 48:1111-1113.
27. van der Linden JW, et al. 2011. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg. Infect. Dis. 17:1846-1854.
28. Van Der Linden JWM, Arendrup MC, Verweij PE, SCARE-Network. 2011. Prospective international surveillance of azole resistance (AR) in Aspergillus fumigatus (Af) (SCARE-Network), abstr. M-490. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
29. Verweij PE, Howard SJ, Melchers WJ, Denning DW. 2009. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist. Updat. 12:141-147.
30. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. 2009. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect. Dis. 9:789-795.
31. Walsh TJ, et al. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360. (Pubitemid 351265310)